CY
CYRX.US Cryoport Inc
- Market cap
- USD 1.01B
- P/E
- -
- P/B
- 2.34x
- ROE
- -7.9%
- Dividend yield
- 0.79%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CYRX.US undervalued?
Graham numberThe Graham number of Cryoport Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cryoport Inc fundamental analysis
No fundamental analysis for Cryoport Inc yet.
Cryoport Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cryoport Inc
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life sc…
Full company profileCryoport Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cryoport Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.68M | 12.0M | 19.6M | 33.9M | 78.7M | 223M | 223M | 237M | 233M | 176M | 196M |
| Gross Profit | 3.10M | 5.97M | 10.2M | 17.4M | 36.3M | 96.6M | 96.6M | 104M | 99.3M | 83.1M | 91.4M |
| Operating Income | -8.77M | -7.89M | -8.64M | -17.7M | -30.0M | -17.8M | -17.8M | -31.9M | -115M | -36.8M | -37.9M |
| EBITDA | -13.4M | -7.21M | -8.61M | -14.5M | -20.3M | -249M | -246M | -1.47M | -63.1M | -2.10M | -9.08M |
| Net Income | -13.1M | -7.90M | -9.56M | -18.3M | -32.7M | -276M | -276M | -37.3M | -99.6M | 78.3M | -38.1M |
| EPS | -0.92 | -0.34 | -0.34 | -0.55 | -0.85 | -6.00 | -6.00 | -0.76 | -2.04 | 1.56 | -0.75 |
| Balance Sheet | |||||||||||
| Total Assets | 8.11M | 20.3M | 56.6M | 136M | 552M | 1.11B | 1.04B | 958M | 703M | 765M | 751M |
| Total Liabilities | 2.43M | 2.38M | 18.1M | 9.59M | 170M | 471M | 483M | 469M | 302M | 262M | 267M |
| Shareholders' Equity | 5.68M | 17.9M | 38.5M | 126M | 383M | 642M | 556M | 489M | 402M | 503M | 484M |
| Cash & Short-term Investments | 4.52M | 15.0M | 47.3M | 94.3M | 93.3M | 629M | 523M | 457M | 262M | 411M | 393M |
| Total Debt | 652K | - | 14.8M | 4.80M | 131M | 427M | 436M | 416M | 251M | 231M | 232M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.72M | -3.58M | -3.35M | -1.32M | -14.9M | 8.13M | -1.85M | -757K | -16.3M | -8.58M | 13.4M |
| Capital Expenditure | 1.07M | 1.80M | 2.96M | 5.41M | 9.67M | 25.0M | 24.2M | 44.9M | 17.3M | 19.5M | 32.5M |
| Free Cash Flow | -6.79M | -5.38M | -6.31M | -6.73M | -24.5M | -16.9M | -26.0M | -45.7M | -33.6M | -28.1M | -19.0M |
| Ratios | |||||||||||
| ROE | -230.9% | -44.2% | -24.8% | -14.5% | -8.5% | -42.9% | -49.6% | -7.6% | -24.8% | 15.6% | -7.9% |
| ROA | -161.7% | -39.0% | -16.9% | -13.5% | -5.9% | -24.8% | -26.5% | -3.9% | -14.2% | 10.2% | -5.1% |
| Net Profit Margin | -170.8% | -66.1% | -48.7% | -54.0% | -41.5% | -123.8% | -123.8% | -15.7% | -42.7% | 44.4% | -19.4% |
| Debt to Equity | 0.11x | - | 0.38x | 0.04x | 0.34x | 0.67x | 0.78x | 0.85x | 0.62x | 0.46x | 0.48x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cryoport Inc dividends
- Dividend yield
- 0.79%
- Forward dividend
- -
- Payout ratio
- 10.2%
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 8.00M | 0.16 | 10.2% |
| 2024 | USD 8.00M | 0.16 | - |
| 2023 | USD 8.00M | 0.16 | - |
| 2022 | USD 8.00M | 0.17 | - |
| 2021 | USD 8.20M | 0.18 | - |
| 2020 | USD 2.84M | 0.07 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:12 on May 19, 2015.
Who owns Cryoport Inc
- Insiders 3.85%
- Institutions 94.54%
- Public & others 1.61%
- Shares outstanding 50.6M
- Free float 46.0M
Top funds holding CYRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.52M | 3.01% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.25M | 2.46% | 0.00% | Oct 2026 |
| First Eagle Small Cap Opportunity I | 1.12M | 2.20% | -2.30% | Sep 2026 |
| Alger Small Cap Focus I | 1.07M | 2.11% | 0.00% | Aug 2026 |
| Calamos Timpani Small Cap Growth I | 605K | 1.19% | -18.54% | Aug 2026 |
| Coeli Circulus Am Micro & Sm Cp I F SEK | 591K | 1.17% | 0.00% | Jun 2026 |
| AXA Framlington Health Fund - R Income | 575K | 1.14% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 542K | 1.07% | 0.00% | Aug 2026 |
| Nuveen Quant Small Cap Equity R6 | 512K | 1.01% | 0.00% | Aug 2026 |
| iShares Russell 2000 Value ETF | 467K | 0.92% | 0.00% | Oct 2026 |
| Brown Capital Mgmt Small Co Inv | 434K | 0.86% | -13.57% | Sep 2026 |
| Needham Aggressive Growth Retail | 360K | 0.71% | +4.79% | Sep 2026 |
| Vanguard Russell 2000 ETF | 288K | 0.57% | +1.07% | Sep 2026 |
| CREF Total Global Stock Account R3 | 273K | 0.54% | -31.38% | Aug 2026 |
| Alger Small Cap Growth A | 272K | 0.54% | +5.39% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 271K | 0.54% | +0.24% | Oct 2026 |
| Royce Micro-Cap Trust | 258K | 0.51% | 0.00% | Sep 2026 |
| Coeli Circulus Micro & Sm Cp I Fdr SEK | 251K | 0.49% | 0.00% | Jun 2026 |
| Needham Small Cap Growth Retail | 240K | 0.47% | -35.73% | Sep 2026 |
| Fidelity Extended Market Index | 236K | 0.47% | -6.42% | Sep 2026 |
Top institutions holding CYRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.22M | 8.33% | +5.97% | Jun 2026 |
| Cadian Capital Management LP | 2.92M | 5.77% | -38.85% | Jun 2026 |
| Arnhold & S. Bleichroeder Advisers, LLC | 2.54M | 5.02% | +241.39% | Jun 2026 |
| Assenagon Asset Management SA | 2.30M | 4.55% | +54.08% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 2.28M | 4.50% | -50.25% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.15M | 4.25% | +1.56% | Jun 2026 |
| Millennium Management LLC | 1.72M | 3.41% | -41.94% | Jun 2026 |
| Fred Alger Management, LLC | 1.55M | 3.05% | -9.07% | Jun 2026 |
| Geode Capital Management, LLC | 1.31M | 2.59% | +5.15% | Jun 2026 |
| Mak Capital One LLC | 1.28M | 2.52% | -10.25% | Jun 2026 |
| State Street Corp | 1.05M | 2.07% | +6.40% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.03M | 2.03% | +2.61% | Sep 2026 |
| Nuveen, LLC | 923K | 1.82% | +817.28% | Jun 2026 |
| UBS Group AG | 868K | 1.71% | -6.92% | Jun 2026 |
| Silvercrest Asset Management Group LLC | 859K | 1.70% | -4.70% | Jun 2026 |
| Meros Investment Management, LP | 743K | 1.47% | +22.04% | Jun 2026 |
| Needham Investment Management, LLC | 717K | 1.42% | +99.17% | Jun 2026 |
| Deutsche Bank AG | 655K | 1.29% | -34.56% | Jun 2026 |
| Acadian Asset Management LLC | 630K | 1.24% | +0.34% | Jun 2026 |
| Intrinsic Edge Capital Management, LLC | 630K | 1.24% | 0.00% | Jun 2026 |
Cryoport Inc company profile
- Company name
- Cryoport Inc
- Ticker
- CYRX.US
- Exchange
- USA Stocks
- Listed since
- Mar 15, 2005
- Sector
- Industrials
- Industry
- Health Care Equipment & Supplies
- Employees
- 684
- Fiscal year end
- December
- Address
- 112 Westwood Place, Brentwood, TN, United States, 37027
- Phone
- 949 470 2300
- Website
- cryoportinc.com
About Cryoport Inc
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostorage, bioservices and cryopreservation services within the life science industry. Its Life Sciences Products segment manufactures, and sells cryogenic freezers, cryogenic dewars, and related ancillary accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport Elite; Cryoport Express Cryogenic HV3 Shipping System; Smartpak Condition Monitoring System and Tec4Med, an IoT-based monitoring solutions; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services; MVE Fusion cryogenic system, a self-sustaining cryogenic freezer; and MVE Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Cryoport Inc management
9- Mr. Jerrell W. SheltonChairman, President & CEO · born 1945
- Mr. Robert S. Stefanovich MSSenior VP, CFO, Treasurer & Chief Administrative Officer · born 1965
- Mr. Edward J. ZecchiniSenior VP and Chief Digital & Technology Officer · born 1962
- Dr. Mark W. Sawicki Ph.D.Senior VP & Chief Scientific Officer
- Mr. Chris LaGulloChief Operating Officer
- Mr. Thomas J. HeinzenVice President of Corporate Development & Investor Relations
- Mr. Tony IppolitoVP, General Counsel & Corporate Secretary
- Ms. Kylie A. CroweVice President of Global Human Resources & Organizational Development
- Mr. Phil WilsonChief Operating Officer of Cryoport Systems, LLC